Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04717050 · ClinicalTrials.gov registry record · NA

Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity

A NA study of Breast Cancer and Stroke, sponsored by Dana-Farber Cancer Institute.

Active
Registry status
NA
Development phase
160
Enrollment target
1
Study location

NCT04717050: Active NA study of Breast Cancer and Stroke, sponsored by Dana-Farber Cancer Institute.

NCT04717050 is a NA study of Breast Cancer and Stroke that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 160 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04717050, a NA study of Breast Cancer and Stroke, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
160 participants
Enrollment target
1
Study location

Study Summary

This study is about testing whether exercise will improve fitness and lessen risk factors related to heart disease, diabetes, and obesity in Latina breast cancer survivors.

Primary Outcome

Visceral adiposity (VA) measured by waist to hip ratio (WHR)

Interventions

  • BEHAVIORAL Progressive combine training (PCT)
  • BEHAVIORAL Attention Control (AC)

Study Locations (1)

Massachusetts

  • Dana Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2021-08-12
Est. Completion 2026-06-15
Phase NA
Dana-Farber Cancer Institute

781 total trials

What the registry record for NCT04717050 still lists

NCT04717050 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower).

The record links to 4 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Progressive combine training (PCT) is the first listed.

NCT04717050 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04717050 about?

NCT04717050 is a clinical study titled "Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity". This study is about testing whether exercise will improve fitness and lessen risk factors related to heart disease, diabetes, and obesity in Latina breast cancer survivors.

What is the current status of trial NCT04717050?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 160 participants. The study started on 2021-08-12. Estimated completion is 2026-06-15.

What conditions does trial NCT04717050 study?

This clinical trial studies the following conditions: Breast Cancer, Stroke, Type 2 Diabetes, Coronary Artery Disease.

What interventions are being tested in trial NCT04717050?

The interventions under investigation include: Progressive combine training (PCT) (BEHAVIORAL), Attention Control (AC) (BEHAVIORAL).

Who is sponsoring clinical trial NCT04717050?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04717050 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04717050's enrollment target sits among peer trials

160 433rd of 1224 higher than 790 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00501826 · 160 participants · Phase 2

    Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

  • NCT00932139 · 160 participants · NA

    Effect of Electro-Acupuncture on Blood Pressure

  • NCT00992901 · 160 participants · Early Phase 1

    Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery

  • NCT01515527 · 160 participants · Phase 2

    Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04717050, the US trial registry maintained by the National Library of Medicine. NCT04717050 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.